Lymphoma Working Party (LWP)
Study type:
Study number:
2010-N-01
Type of treatment:
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
NIS CTCL
Primary objective:
Key inclusion criteria:
Advanced stage (IIB or greater) Mycosis Fungeoïdes and Sézary Syndrome, over 18 years old, Reinduction chemotherapy, ECOG performance 0-2. Exclusion criteria: ex-vivo T-cell depletion with Alentuzumab
Country:
Principal investigator:
Rafael Duarte
EBMT Study coordinator:
Hervé Finel